Understanding Metastatic Breast Cancer Drugs: 6 Key Treatment Approaches

Explore the main categories of drugs used to manage metastatic breast cancer. Learn about hormone therapy, targeted therapies, chemotherapy, and immunotherapy options.

Understanding Metastatic Breast Cancer Drugs: 6 Key Treatment Approaches

Metastatic breast cancer (MBC) refers to breast cancer that has spread from the original tumor site to other parts of the body, such as the bones, liver, lungs, or brain. While it is not typically curable, various drug therapies are available to help manage the disease, alleviate symptoms, and improve quality of life. Treatment decisions are highly individualized, depending on the cancer's specific characteristics, previous treatments, and the patient's overall health.

The selection of metastatic breast cancer drugs is a complex process guided by medical professionals. Here are six essential categories of drug-based approaches commonly employed:

1. Hormone Therapy


Hormone therapy is a primary treatment for hormone receptor-positive (HR-positive) metastatic breast cancer, meaning the cancer cells have receptors for estrogen and/or progesterone. These drugs work by blocking the hormones from reaching cancer cells or by reducing the body's production of hormones. Common types include:



  • Selective Estrogen Receptor Modulators (SERMs):

    Such as Tamoxifen, which blocks estrogen receptors on cancer cells.

  • Aromatase Inhibitors (AIs):

    Such as Anastrozole, Letrozole, and Exemestane, which reduce estrogen production in postmenopausal women.

  • Selective Estrogen Receptor Degraders (SERDs):

    Such as Fulvestrant, which causes the degradation of estrogen receptors.


These therapies aim to slow or stop the growth of HR-positive cancer cells.

2. Targeted Therapies


Targeted therapies are designed to interfere with specific molecules involved in cancer growth and progression, often with less harm to normal cells compared to traditional chemotherapy. They are effective when the cancer cells possess particular targets:



  • HER2-Targeted Therapies:

    For HER2-positive MBC, drugs like Trastuzumab, Pertuzumab, and Lapatinib target the HER2 protein that promotes cancer cell growth.

  • CDK4/6 Inhibitors:

    Drugs such as Palbociclib, Ribociclib, and Abemaciclib are used in combination with hormone therapy for HR-positive, HER2-negative MBC. They block enzymes that control cell division.

  • mTOR Inhibitors:

    Everolimus is an example used for HR-positive, HER2-negative MBC that has progressed on previous hormone therapy.

  • PARP Inhibitors:

    Olaparib and Talazoparib are options for specific types of MBC, particularly in patients with germline BRCA mutations.


The presence of these targets is determined through specific diagnostic testing.

3. Chemotherapy


Chemotherapy drugs work by destroying rapidly dividing cells, including cancer cells. It is often a primary treatment option for triple-negative breast cancer (TNBC) and for cancers that are no longer responding to hormone or targeted therapies. Chemotherapy may also be used for specific clinical situations in other subtypes. Common chemotherapy agents used for MBC include:



  • Anthracyclines (e.g., Doxorubicin)

  • Taxanes (e.g., Paclitaxel, Docetaxel)

  • Capecitabine

  • Gemcitabine

  • Eribulin


Chemotherapy can be administered in various combinations and schedules, tailored to the individual's needs and the cancer's response.

4. Immunotherapy


Immunotherapy drugs help the body's own immune system recognize and fight cancer cells. For metastatic breast cancer, immunotherapy is primarily an option for a subset of triple-negative breast cancer (TNBC) that expresses PD-L1.



  • PD-1/PD-L1 Inhibitors:

    Atezolizumab and Pembrolizumab are examples of checkpoint inhibitors that block proteins (PD-1 or PD-L1) that cancer cells use to evade the immune system. By blocking these checkpoints, the immune system can more effectively attack cancer cells.


Immunotherapy is typically used in combination with chemotherapy for eligible patients with advanced TNBC.

5. Antibody-Drug Conjugates (ADCs)


ADCs are a newer class of targeted therapy that combine an antibody with a chemotherapy drug. The antibody specifically targets a protein on the cancer cell surface, delivering the chemotherapy directly to the tumor cells while sparing healthy cells to a greater extent. Examples include:



  • Trastuzumab Deruxtecan:

    For HER2-positive and HER2-low MBC.

  • Sacituzumab Govitecan:

    For specific types of HR-positive and triple-negative MBC.


These drugs represent an advancement in delivering potent anti-cancer agents more precisely to tumor sites.

6. Bone-Targeting Drugs


When metastatic breast cancer spreads to the bones, it can cause pain, fractures, and other complications. While not directly anti-cancer drugs, bone-targeting agents are often used alongside other treatments to manage bone metastases and improve bone health. These include:



  • Bisphosphonates:

    Such as Zoledronic Acid and Pamidronate, which help strengthen bones and reduce bone-related events.

  • RANK Ligand Inhibitors:

    Such as Denosumab, which also helps prevent bone complications by inhibiting bone breakdown.


These drugs are crucial for managing symptoms and preventing skeletal complications associated with bone metastases.

Summary


The landscape of metastatic breast cancer drugs is continually evolving, offering a range of options to manage the disease. Treatment approaches are highly personalized, considering the specific characteristics of the cancer (such as hormone receptor status, HER2 status, and genetic mutations), previous therapies, and the individual's overall health. Key drug categories include hormone therapy, various targeted therapies, chemotherapy, immunotherapy, antibody-drug conjugates, and bone-targeting agents. All treatment decisions are made by a multidisciplinary team of healthcare professionals to optimize outcomes and support the individual's well-being.